董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Eansor | 男 | Chairman and Director | 65 | 30.84万美元 | 未持股 | 2026-05-01 |
| Juan Vera | 男 | Chief Executive Officer and Director and President and Principal Financial Officer | 46 | 68.14万美元 | 未持股 | 2026-05-01 |
| Katharine Knobil | 女 | Director | 62 | 26.99万美元 | 未持股 | 2026-05-01 |
| Steven Elms | 男 | Director | 62 | 26.19万美元 | 未持股 | 2026-05-01 |
| Maria Bernadette Madel | 女 | Director, Corporate Operations and External Communications | 36 | 未披露 | 未持股 | 2026-05-01 |
| Kathryn Penkus Corzo | 女 | Director | 64 | 13.00万美元 | 未持股 | 2026-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Juan Vera | 男 | Chief Executive Officer and Director and President and Principal Financial Officer | 46 | 68.14万美元 | 未持股 | 2026-05-01 |
| Maria Bernadette Madel | 女 | Director, Corporate Operations and External Communications | 36 | 未披露 | 未持股 | 2026-05-01 |
董事简历
中英对照 | 中文 | 英文- David Eansor
-
David Eansor从Novus Biologicals于2014年7月2日完成对Novus的收购后就担任Novus Biologicals的高级副总裁。从2013年1月直到收购之日，Eansor先生担任Novus Biologicals的公司发展部的高级副总裁。加入Novus前，Eansor先生担任赛默飞世尔科技（Thermo Fisher Scientific）的生物科学部门的总裁。Eansor先生于2010年初晋升为部门总经理，之前在赛默飞世尔科技公司的生命科学研究业务部担任总裁达5年。
David Eansor joined the Board in October 2018 and became the chair of the Board following the Annual Meeting in 2022. Mr. Eansor served as the President of the Protein Sciences Segment of Bio Techne Corporation from April 2018 until his retirement in March 2022. From 2014 to April 2018, Mr. Eansor served as Senior Vice President of Bio Techne's Biotechnology Division, which he joined as result of Bio Techne's acquisition of Nov Biologicals. Mr. Eansor earned a B.S. in Chemistry from University of stern Ontario, as ll as a Bachelor of Commerce in General Biness and Economics and an M.B.A. from the University of Windsor, Ontario, Canada. - David Eansor从Novus Biologicals于2014年7月2日完成对Novus的收购后就担任Novus Biologicals的高级副总裁。从2013年1月直到收购之日，Eansor先生担任Novus Biologicals的公司发展部的高级副总裁。加入Novus前，Eansor先生担任赛默飞世尔科技（Thermo Fisher Scientific）的生物科学部门的总裁。Eansor先生于2010年初晋升为部门总经理，之前在赛默飞世尔科技公司的生命科学研究业务部担任总裁达5年。
- David Eansor joined the Board in October 2018 and became the chair of the Board following the Annual Meeting in 2022. Mr. Eansor served as the President of the Protein Sciences Segment of Bio Techne Corporation from April 2018 until his retirement in March 2022. From 2014 to April 2018, Mr. Eansor served as Senior Vice President of Bio Techne's Biotechnology Division, which he joined as result of Bio Techne's acquisition of Nov Biologicals. Mr. Eansor earned a B.S. in Chemistry from University of stern Ontario, as ll as a Bachelor of Commerce in General Biness and Economics and an M.B.A. from the University of Windsor, Ontario, Canada.
- Juan Vera
-
Juan Vera是该公司的联合创始人，自2018年以来一直担任我们的董事会成员。从2013年到2018年，他是公司的管理成员。威尔逊先生于2015年至2018年担任他共同创立的MarkerTherapeutics，Inc.的首席执行官，目前担任纳斯达克股票代码:MRKR的董事会成员。1996年以来，他一直担任Wilson Wolf Manufacturing Corporation（生物技术领域的细胞培养设备的设计、开发和制造）的首席执行官。他获得了50多项相关专利，目前正在申请多项专利。Wilson先生是G-Rex细胞培养平台的共同发明人，该平台广泛用于T细胞的大规模生产，以及。是Mark Therapeutics’；多肿瘤相关抗原技术的共同发明人。Wilson先生拥有明尼苏达州汉姆林大学（Hamline University）的工商管理学士学位和经济学学士学位，以及明尼苏达大学（University of Minnesota）的机械工程学士学位。
Juan Vera began service as President and Chief Executive Officer effective May 1, 2023. Dr. Vera also serves as Principal Executive Officer and Principal Financial Officer. He joined the Board in October 2018 and previoly served as Chief Operating Officer from November 2021 to April 2023 and served as Chief Scientific Officer from October 2018 to April 2023. Dr. Vera is a co inventor of the Multi Antigen Recognizing (MAR) T cell technology and co founder of predecessor, Marker Cell Therapy, Inc. Dr. Vera has held vario positions at the Center for Cell and Gene Therapy at Baylor College of Medicine, most recently was an Associate Professor at Baylor. Dr. Vera received the Idea Development Award from the Department of Defense and Mentored Research Scholar Award from the American Cancer Society. - Juan Vera是该公司的联合创始人，自2018年以来一直担任我们的董事会成员。从2013年到2018年，他是公司的管理成员。威尔逊先生于2015年至2018年担任他共同创立的MarkerTherapeutics，Inc.的首席执行官，目前担任纳斯达克股票代码:MRKR的董事会成员。1996年以来，他一直担任Wilson Wolf Manufacturing Corporation（生物技术领域的细胞培养设备的设计、开发和制造）的首席执行官。他获得了50多项相关专利，目前正在申请多项专利。Wilson先生是G-Rex细胞培养平台的共同发明人，该平台广泛用于T细胞的大规模生产，以及。是Mark Therapeutics’；多肿瘤相关抗原技术的共同发明人。Wilson先生拥有明尼苏达州汉姆林大学（Hamline University）的工商管理学士学位和经济学学士学位，以及明尼苏达大学（University of Minnesota）的机械工程学士学位。
- Juan Vera began service as President and Chief Executive Officer effective May 1, 2023. Dr. Vera also serves as Principal Executive Officer and Principal Financial Officer. He joined the Board in October 2018 and previoly served as Chief Operating Officer from November 2021 to April 2023 and served as Chief Scientific Officer from October 2018 to April 2023. Dr. Vera is a co inventor of the Multi Antigen Recognizing (MAR) T cell technology and co founder of predecessor, Marker Cell Therapy, Inc. Dr. Vera has held vario positions at the Center for Cell and Gene Therapy at Baylor College of Medicine, most recently was an Associate Professor at Baylor. Dr. Vera received the Idea Development Award from the Department of Defense and Mentored Research Scholar Award from the American Cancer Society.
- Katharine Knobil
-
Katharine Knobil，此前于2021年4月至2024年1月担任实验室产品和软件公司安捷伦科技公司的首席医疗官。此前，Knobil博士曾于2018年12月至2021年1月在Kaleido Biosciences, Inc.担任首席医疗官兼研发主管，该公司是一家临床阶段的医疗保健公司，目标是利用微生物组治疗疾病和改善健康。Knobil博士在制药公司葛兰素史克（GSK）担任越来越多的职责20多年，最近于2017年12月至2018年12月担任公司首席医疗官，负责监督制药、疫苗和消费者业务的医疗事务、健康结果、全球临床安全和医疗治理。此前，她曾于2015年11月至2017年12月担任GSK制药部门的首席医疗官，在此之前，她担任高级副总裁、价值证据和结果。Knobil博士于1997年首次加入GSK，担任呼吸临床开发的研究医师，随后担任多个职务，包括领导欧洲呼吸临床团队，以及在中国建设所有治疗领域的后期临床开发。Knobil博士被FiercePharma评为2018年生命科学领域最激烈的女性之一。Knobil博士目前担任Marker Therapeutics, Inc.（纳斯达克：MRKR）的董事会成员，自2021年12月起担任Pliant Therapeutics, Inc.（纳斯达克：PLRX）的董事会成员，自2022年9月起担任Nimbus Therapeutics，LLC的董事会成员，自2024年2月起担任Infinant Health，Inc.的董事会成员，自2025年3月起担任。从2020年6月到2022年3月，她一直是阿里那制药公司的董事会成员，直到该公司被辉瑞收购。Knobil博士获得了康奈尔大学的学士学位、得克萨斯大学西南医学院的医学博士学位，并在约翰霍普金斯医学院完成了肺部和重症医学的研究金。
Katharine Knobil joined the Board in December 2021. Dr. Knobil currently serves as Chief Medical Officer at Altesa BioSciences, Inc. and previoly served as Chief Medical Officer of Agilent Technologies Inc., a position she held from April 2021 to January 2024. Dr. Knobil previoly served as Chief Medical Officer and Head of Research & Development at Kaleido Biosciences, Inc. from December 2018 to January 2021. Previoly, Dr. Knobil spent more than 20 years in roles of increasing responsibility at GlaxoSmithKline plc, most recently serving as the corporate Chief Medical Officer from 2017 to December 2018, and as Chief Medical Officer for Pharmaceuticals at GSK from 2015 to 2017. She served as a member of the board of directors of Arena Pharmaceuticals, Inc. from June 2020 until its acquisition by Pfizer Inc. in March 2022. Dr. Knobil currently serves on the Board of Directors of Nimb Therapeutics, LLC, KorroBio, Inc. and Pliant Therapeutics, Inc. Dr. Knobil received her B.A. from Cornell University, her M.D. from University of Texas Southstern Medical School, and completed a Fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins Medical School. - Katharine Knobil，此前于2021年4月至2024年1月担任实验室产品和软件公司安捷伦科技公司的首席医疗官。此前，Knobil博士曾于2018年12月至2021年1月在Kaleido Biosciences, Inc.担任首席医疗官兼研发主管，该公司是一家临床阶段的医疗保健公司，目标是利用微生物组治疗疾病和改善健康。Knobil博士在制药公司葛兰素史克（GSK）担任越来越多的职责20多年，最近于2017年12月至2018年12月担任公司首席医疗官，负责监督制药、疫苗和消费者业务的医疗事务、健康结果、全球临床安全和医疗治理。此前，她曾于2015年11月至2017年12月担任GSK制药部门的首席医疗官，在此之前，她担任高级副总裁、价值证据和结果。Knobil博士于1997年首次加入GSK，担任呼吸临床开发的研究医师，随后担任多个职务，包括领导欧洲呼吸临床团队，以及在中国建设所有治疗领域的后期临床开发。Knobil博士被FiercePharma评为2018年生命科学领域最激烈的女性之一。Knobil博士目前担任Marker Therapeutics, Inc.（纳斯达克：MRKR）的董事会成员，自2021年12月起担任Pliant Therapeutics, Inc.（纳斯达克：PLRX）的董事会成员，自2022年9月起担任Nimbus Therapeutics，LLC的董事会成员，自2024年2月起担任Infinant Health，Inc.的董事会成员，自2025年3月起担任。从2020年6月到2022年3月，她一直是阿里那制药公司的董事会成员，直到该公司被辉瑞收购。Knobil博士获得了康奈尔大学的学士学位、得克萨斯大学西南医学院的医学博士学位，并在约翰霍普金斯医学院完成了肺部和重症医学的研究金。
- Katharine Knobil joined the Board in December 2021. Dr. Knobil currently serves as Chief Medical Officer at Altesa BioSciences, Inc. and previoly served as Chief Medical Officer of Agilent Technologies Inc., a position she held from April 2021 to January 2024. Dr. Knobil previoly served as Chief Medical Officer and Head of Research & Development at Kaleido Biosciences, Inc. from December 2018 to January 2021. Previoly, Dr. Knobil spent more than 20 years in roles of increasing responsibility at GlaxoSmithKline plc, most recently serving as the corporate Chief Medical Officer from 2017 to December 2018, and as Chief Medical Officer for Pharmaceuticals at GSK from 2015 to 2017. She served as a member of the board of directors of Arena Pharmaceuticals, Inc. from June 2020 until its acquisition by Pfizer Inc. in March 2022. Dr. Knobil currently serves on the Board of Directors of Nimb Therapeutics, LLC, KorroBio, Inc. and Pliant Therapeutics, Inc. Dr. Knobil received her B.A. from Cornell University, her M.D. from University of Texas Southstern Medical School, and completed a Fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins Medical School.
- Steven Elms
-
Steven Elms目前在生命科学投资公司Aisling Capital担任管理合伙人，他于2000年加入该公司。Elms先生自2007年起担任ADMA Biologics，Inc.的董事会主席，自2019年5月起担任Elevation Oncology。此前于2018年5月至2022年5月担任Zosano Pharma公司董事会成员，于2013年至2019年2月担任LOXO Oncology董事。Elms先生获得了斯坦福大学人体生物学学士学位和西北大学家乐氏管理研究生院工商管理硕士学位。
Steven Elms joined the Board in Augt 2019, and previoly served as a non voting board observer. Mr. Elms currently serves as Managing Partner at Aisling Capital, a life sciences investment firm, which he joined in 2000. Mr. Elms has served as chairman of the board of directors of ADMA Biologics, Inc. since 2007 and Elevation Oncology, Inc. since May 2019. He previoly served as a member of the board of directors of Zosano Pharma Corp. from May 2018 to May 2022 and as a director of LOXO Oncology from 2013 to February 2019. Mr. Elms earned a B.A. in Human Biology from Stanford University and an M.B.A. from the Kellogg Graduate School of Management at Northstern University. - Steven Elms目前在生命科学投资公司Aisling Capital担任管理合伙人，他于2000年加入该公司。Elms先生自2007年起担任ADMA Biologics，Inc.的董事会主席，自2019年5月起担任Elevation Oncology。此前于2018年5月至2022年5月担任Zosano Pharma公司董事会成员，于2013年至2019年2月担任LOXO Oncology董事。Elms先生获得了斯坦福大学人体生物学学士学位和西北大学家乐氏管理研究生院工商管理硕士学位。
- Steven Elms joined the Board in Augt 2019, and previoly served as a non voting board observer. Mr. Elms currently serves as Managing Partner at Aisling Capital, a life sciences investment firm, which he joined in 2000. Mr. Elms has served as chairman of the board of directors of ADMA Biologics, Inc. since 2007 and Elevation Oncology, Inc. since May 2019. He previoly served as a member of the board of directors of Zosano Pharma Corp. from May 2018 to May 2022 and as a director of LOXO Oncology from 2013 to February 2019. Mr. Elms earned a B.A. in Human Biology from Stanford University and an M.B.A. from the Kellogg Graduate School of Management at Northstern University.
- Maria Bernadette Madel
-
Maria Bernadette Madel，在贝勒医学院等学术机构积累了宝贵经验后，于2022年加入公司。马德尔博士在奥地利因斯布鲁克医科大学获得分子医学理学学士和理学硕士学位，在法国尼斯蔚蓝海岸大学获得免疫学和微生物学博士学位。
Maria Bernadette Madel has served as Director of Corporate Operations and External Communications since December 2023. Dr. Madel joined the Company in 2022 after accruing valuable experience in academic institutions, including Baylor College of Medicine. - Maria Bernadette Madel，在贝勒医学院等学术机构积累了宝贵经验后，于2022年加入公司。马德尔博士在奥地利因斯布鲁克医科大学获得分子医学理学学士和理学硕士学位，在法国尼斯蔚蓝海岸大学获得免疫学和微生物学博士学位。
- Maria Bernadette Madel has served as Director of Corporate Operations and External Communications since December 2023. Dr. Madel joined the Company in 2022 after accruing valuable experience in academic institutions, including Baylor College of Medicine.
- Kathryn Penkus Corzo
-
Kathryn Penkus Corzo，于2021年9月至2024年11月期间在Matinas Biopharma Holdings，Inc.的董事会任职，现任bit.Bio总裁兼首席运营官。在加入bit.bio之前，Corzo女士是Takeda Ventures，Inc.的合伙人，该公司是Takeda Pharmaceutical Company Limited（TSE：4502/NYSE：TAK）（“武田”）的企业投资部门，也是全球生物制药公司Takeda的肿瘤细胞疗法开发负责人，她自2020年以来一直担任该职位。在加入武田之前，Corzo女士是研发全球制药主管的副总裁，2015年至2019年，她在赛诺菲（SAN.PA）负责监督骨髓瘤产品组合，还于2010年至2015年在赛诺菲的专科护理全球业务部门赛诺菲 Genzyme担任越来越重要的职务。在加入赛诺菲之前，Corzo女士曾于1989年至2010年在Hoffman – La Roche、Roche Molecular Systems、礼来和Syndax任职，在此期间，她在运营、全球临床开发、医疗事务、业务发展、市场准入以及跨多个治疗产品和适应症的品牌管理方面担任管理和领导职务。
Kathryn Penkus Corzo served on the Board of Directors of Matinas Biopharma Holdings, Inc. beten September 2021 and November 2024 and is currently the President and Chief Operating Officer of bit.bio. Prior to bit.bio, Ms. Corzo was a partner at Takeda Ventures, Inc., the corporate investment arm of Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda"), and the head of the Oncology Cell Therapy Development at Takeda, a global biopharmaceutical company, a position she has held since 2020. Prior to joining Takeda, Ms. Corzo was Vice President of the R&D Global Pharma Head where she oversaw the Myeloma portfolio from 2015 to 2019 at Sanofi (SAN.PA) and also held positions of increasing responsibility at Sanofi Genzyme, a specialty care global biness unit of Sanofi, from 2010 to 2015. Prior to joining Sanofi, Ms. Corzo worked at Hoffman-La Roche, Roche Molecular Systems, Eli Lilly and Syndax from 1989 to 2010, during which time she held management and leadership roles in operations, global clinical development, medical affairs, biness development, market access and brand management across multiple therapeutic products and indications. - Kathryn Penkus Corzo，于2021年9月至2024年11月期间在Matinas Biopharma Holdings，Inc.的董事会任职，现任bit.Bio总裁兼首席运营官。在加入bit.bio之前，Corzo女士是Takeda Ventures，Inc.的合伙人，该公司是Takeda Pharmaceutical Company Limited（TSE：4502/NYSE：TAK）（“武田”）的企业投资部门，也是全球生物制药公司Takeda的肿瘤细胞疗法开发负责人，她自2020年以来一直担任该职位。在加入武田之前，Corzo女士是研发全球制药主管的副总裁，2015年至2019年，她在赛诺菲（SAN.PA）负责监督骨髓瘤产品组合，还于2010年至2015年在赛诺菲的专科护理全球业务部门赛诺菲 Genzyme担任越来越重要的职务。在加入赛诺菲之前，Corzo女士曾于1989年至2010年在Hoffman – La Roche、Roche Molecular Systems、礼来和Syndax任职，在此期间，她在运营、全球临床开发、医疗事务、业务发展、市场准入以及跨多个治疗产品和适应症的品牌管理方面担任管理和领导职务。
- Kathryn Penkus Corzo served on the Board of Directors of Matinas Biopharma Holdings, Inc. beten September 2021 and November 2024 and is currently the President and Chief Operating Officer of bit.bio. Prior to bit.bio, Ms. Corzo was a partner at Takeda Ventures, Inc., the corporate investment arm of Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda"), and the head of the Oncology Cell Therapy Development at Takeda, a global biopharmaceutical company, a position she has held since 2020. Prior to joining Takeda, Ms. Corzo was Vice President of the R&D Global Pharma Head where she oversaw the Myeloma portfolio from 2015 to 2019 at Sanofi (SAN.PA) and also held positions of increasing responsibility at Sanofi Genzyme, a specialty care global biness unit of Sanofi, from 2010 to 2015. Prior to joining Sanofi, Ms. Corzo worked at Hoffman-La Roche, Roche Molecular Systems, Eli Lilly and Syndax from 1989 to 2010, during which time she held management and leadership roles in operations, global clinical development, medical affairs, biness development, market access and brand management across multiple therapeutic products and indications.
高管简历
中英对照 | 中文 | 英文- Juan Vera
Juan Vera是该公司的联合创始人，自2018年以来一直担任我们的董事会成员。从2013年到2018年，他是公司的管理成员。威尔逊先生于2015年至2018年担任他共同创立的MarkerTherapeutics，Inc.的首席执行官，目前担任纳斯达克股票代码:MRKR的董事会成员。1996年以来，他一直担任Wilson Wolf Manufacturing Corporation（生物技术领域的细胞培养设备的设计、开发和制造）的首席执行官。他获得了50多项相关专利，目前正在申请多项专利。Wilson先生是G-Rex细胞培养平台的共同发明人，该平台广泛用于T细胞的大规模生产，以及。是Mark Therapeutics’；多肿瘤相关抗原技术的共同发明人。Wilson先生拥有明尼苏达州汉姆林大学（Hamline University）的工商管理学士学位和经济学学士学位，以及明尼苏达大学（University of Minnesota）的机械工程学士学位。
Juan Vera began service as President and Chief Executive Officer effective May 1, 2023. Dr. Vera also serves as Principal Executive Officer and Principal Financial Officer. He joined the Board in October 2018 and previoly served as Chief Operating Officer from November 2021 to April 2023 and served as Chief Scientific Officer from October 2018 to April 2023. Dr. Vera is a co inventor of the Multi Antigen Recognizing (MAR) T cell technology and co founder of predecessor, Marker Cell Therapy, Inc. Dr. Vera has held vario positions at the Center for Cell and Gene Therapy at Baylor College of Medicine, most recently was an Associate Professor at Baylor. Dr. Vera received the Idea Development Award from the Department of Defense and Mentored Research Scholar Award from the American Cancer Society.- Juan Vera是该公司的联合创始人，自2018年以来一直担任我们的董事会成员。从2013年到2018年，他是公司的管理成员。威尔逊先生于2015年至2018年担任他共同创立的MarkerTherapeutics，Inc.的首席执行官，目前担任纳斯达克股票代码:MRKR的董事会成员。1996年以来，他一直担任Wilson Wolf Manufacturing Corporation（生物技术领域的细胞培养设备的设计、开发和制造）的首席执行官。他获得了50多项相关专利，目前正在申请多项专利。Wilson先生是G-Rex细胞培养平台的共同发明人，该平台广泛用于T细胞的大规模生产，以及。是Mark Therapeutics’；多肿瘤相关抗原技术的共同发明人。Wilson先生拥有明尼苏达州汉姆林大学（Hamline University）的工商管理学士学位和经济学学士学位，以及明尼苏达大学（University of Minnesota）的机械工程学士学位。
- Juan Vera began service as President and Chief Executive Officer effective May 1, 2023. Dr. Vera also serves as Principal Executive Officer and Principal Financial Officer. He joined the Board in October 2018 and previoly served as Chief Operating Officer from November 2021 to April 2023 and served as Chief Scientific Officer from October 2018 to April 2023. Dr. Vera is a co inventor of the Multi Antigen Recognizing (MAR) T cell technology and co founder of predecessor, Marker Cell Therapy, Inc. Dr. Vera has held vario positions at the Center for Cell and Gene Therapy at Baylor College of Medicine, most recently was an Associate Professor at Baylor. Dr. Vera received the Idea Development Award from the Department of Defense and Mentored Research Scholar Award from the American Cancer Society.
- Maria Bernadette Madel
Maria Bernadette Madel，在贝勒医学院等学术机构积累了宝贵经验后，于2022年加入公司。马德尔博士在奥地利因斯布鲁克医科大学获得分子医学理学学士和理学硕士学位，在法国尼斯蔚蓝海岸大学获得免疫学和微生物学博士学位。
Maria Bernadette Madel has served as Director of Corporate Operations and External Communications since December 2023. Dr. Madel joined the Company in 2022 after accruing valuable experience in academic institutions, including Baylor College of Medicine.- Maria Bernadette Madel，在贝勒医学院等学术机构积累了宝贵经验后，于2022年加入公司。马德尔博士在奥地利因斯布鲁克医科大学获得分子医学理学学士和理学硕士学位，在法国尼斯蔚蓝海岸大学获得免疫学和微生物学博士学位。
- Maria Bernadette Madel has served as Director of Corporate Operations and External Communications since December 2023. Dr. Madel joined the Company in 2022 after accruing valuable experience in academic institutions, including Baylor College of Medicine.